Play all audios:
Access through your institution Buy or subscribe PERSISTENT INFECTION WITH HIGH-RISK TYPES OF HUMAN PAPILLOMAVIRUS (HPV) CAUSES ALMOST ALL CERVICAL CANCERS. TWO HPV VACCINES HAVE BEEN
LICENSED FOR PROPHYLACTIC VACCINATION IN MANY COUNTRIES AND HAVE BEEN HIGHLY EFFECTIVE AT PREVENTING INFECTION BY THE VACCINE-TARGETED HPV TYPES. TWO RECENT PAPERS DESCRIBE THE FOUR-YEAR,
END-OF-STUDY DATA FROM A LARGE-SCALE TRIAL OF CERVARIX, A VACCINE THAT TARGETS THE MOST PREVALENT ONCOGENIC HPV TYPES 16 AND 18, IN WOMEN AGED 15–25 YEARS 1, 2 . THE RESULTS INDICATE THAT
THE VACCINE HAS HIGH EFFICACY AGAINST CERVICAL PRECANCER DEVELOPMENT AND IS CROSS PROTECTIVE AGAINST NONVACCINE ONCOGENIC HPV TYPES. WE ASKED FOUR EXPERTS TO COMMENT ON THIS TRIAL AND THE
IMPLICATIONS FOR VACCINATION AND CERVICAL CANCER SCREENING POLICIES. JANE KIM This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your
institution Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access
to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read
our FAQs * Contact customer support REFERENCES * Lehtinen, M. et al. _Lancet Oncol._ published online, 10.1016/S1470-2045(11)70286-8 (8 November 2011). * Wheeler, C. et al. _Lancet Oncol._
published online, 10.1016/S1470-2045(11)70287-X (8 November 2011). * Brown, D.R. et al. _J. Infect. Dis._ 199, 926–935 (2009). Article Google Scholar * Hoy, T., Singhal, P.K., Willey, V.J.
& Insinga, R.P. _Curr. Med. Res. Opin._ 25, 2343–2351 (2009). Article Google Scholar * Goldie, S.J. et al. _Vaccine_ 26, 4080–4093 (2008). Article Google Scholar * Muñoz, N. et al.
_J. Natl. Cancer Inst._ 102, 325–339 (2010). Article Google Scholar * Lowy, D.R., Solomon, D., Hildesheim, A., Schiller, J.T. & Schiffman, M. _Cancer_ 113, Suppl. 7, 1980–1993 (2008).
Article Google Scholar * Brotherton, J.M. et al. _Lancet_ 377, 2085–2092 (2011). Article Google Scholar * Gee, J. et al. _Vaccine_ 29, 8279–8284 (2011). Article Google Scholar *
Einstein, M.H. et al. _Hum. Vaccin._ 7, 1359–1373 (2011). Article CAS Google Scholar * Romanowski, B. et al. _Lancet_ 374, 1975–1985 (2009). Article CAS Google Scholar * Kjær, S.K.,
Frederiksen, K., Munk, C. & Iftner, T. _J. Natl. Cancer Inst._ 102, 1478–1488 (2010). Article Google Scholar * Barr, E. et al. _Am. J. Obstet. Gynecol._ 198, 261.e1–261.e11 (2008).
Article Google Scholar * Centers for Disease Control and Prevention. _MMWR Morb. Mortal. Wkly. Rep._ 59, 626–629 (2010). Download references ETHICS DECLARATIONS COMPETING INTERESTS
K.K.S.-M. is on the scientific and clinical advisory board and has stock options for OncoHealth, a company developing diagnostic tests for cervical cancer screening. D.R.L. is an inventor on
US government–owned human papilloma virus vaccine patents that are licensed to Glaxo-Smith Kline and Merck and is entitled to limited royalties as specified by law. C.J.M.M. is chief
scientific officer of ISA Pharmaceuticals. This company develops synthetic therapeutic vaccines. In theory, such vaccines can also possess preventive activity, although no preventive
activity against HPV16 or HPV18 has been shown by ISA. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE The value of HPV vaccination. _Nat Med_ 18, 28–29
(2012). https://doi.org/10.1038/nm0112-28 Download citation * Published: 06 January 2012 * Issue Date: January 2012 * DOI: https://doi.org/10.1038/nm0112-28 SHARE THIS ARTICLE Anyone you
share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the
Springer Nature SharedIt content-sharing initiative